NYSEAMERICAN:OCX - OncoCyte Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.48 -0.31 (-6.47 %) (As of 05/24/2019 04:00 PM ET)Previous Close$4.79Today's Range$4.45 - $4.8952-Week Range$1.16 - $6.92Volume93,882 shsAverage Volume898,626 shsMarket Capitalization$232.84 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc. Receive OCX News and Ratings via Email Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:OCX Previous SymbolAMEX:OCX CUSIPN/A CIK1642380 Webhttp://www.oncocyte.com/ Phone(510) 775-0515Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees12 Outstanding Shares51,973,000Market Cap$232.84 million Next Earnings Date8/13/2019 (Estimated) OptionableNot Optionable OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions What is OncoCyte's stock symbol? OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX." How were OncoCyte's earnings last quarter? OncoCyte Corp (NYSEAMERICAN:OCX) posted its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. View OncoCyte's Earnings History. When is OncoCyte's next earnings date? OncoCyte is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for OncoCyte. What price target have analysts set for OCX? 5 Wall Street analysts have issued twelve-month price targets for OncoCyte's shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate OncoCyte's share price to reach $7.00 in the next year. This suggests a possible upside of 56.3% from the stock's current price. View Analyst Price Targets for OncoCyte. What is the consensus analysts' recommendation for OncoCyte? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte. Has OncoCyte been receiving favorable news coverage? News stories about OCX stock have trended positive on Saturday, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. OncoCyte earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. Are investors shorting OncoCyte? OncoCyte saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 828,304 shares, an increase of 6.1% from the April 15th total of 780,426 shares. Based on an average trading volume of 126,270 shares, the days-to-cover ratio is presently 6.6 days. Approximately 2.8% of the company's shares are short sold. View OncoCyte's Current Options Chain. Who are some of OncoCyte's key competitors? Some companies that are related to OncoCyte include ProMetic Life Sciences (PLI), Mesoblast (MSB), Polynovo (PNV), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Starpharma (SPL), Biotest (BIO), Oxford BioMedica (OXB), Neptune Wellness Solutions (NEPT), Theratechnologies (TH), Senesco Technologies (ELOX), Kodiak Sciences (KOD), IMV (IMV), Monash IVF Group (MVF) and Paradigm Biopharmaceuticals (PAR). What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include BioTime (BTX), Alnylam Pharmaceuticals (ALNY), Novocure (NVCR), Alibaba Group (BABA), Geron (GERN), Asterias Biotherapeutics (AST), Apricus Biosciences (APRI), Anavex Life Sciences (AVXL), Progenics Pharmaceuticals (PGNX) and AVEO Pharmaceuticals (AVEO). Who are OncoCyte's key executives? OncoCyte's management team includes the folowing people: Mr. William Annett, Pres, CEO & Director (Age 65)Mr. Mitchell S. Levine, Chief Financial OfficerDr. Lyndal K. Hesterberg, Chief Scientific OfficerMr. Albert P. Parker II, Chief Operating OfficerDr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66) Who are OncoCyte's major shareholders? OncoCyte's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.79%), Schonfeld Strategic Advisors LLC (1.67%), Renaissance Technologies LLC (0.26%), BlackRock Inc. (0.24%), Northern Trust Corp (0.11%) and JPMorgan Chase & Co. (0.09%). View Institutional Ownership Trends for OncoCyte. Which major investors are buying OncoCyte stock? OCX stock was purchased by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Spark Investment Management LLC and Virtu Financial LLC. View Insider Buying and Selling for OncoCyte. How do I buy shares of OncoCyte? Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OncoCyte's stock price today? One share of OCX stock can currently be purchased for approximately $4.48. How big of a company is OncoCyte? OncoCyte has a market capitalization of $232.84 million. OncoCyte employs 12 workers across the globe. What is OncoCyte's official website? The official website for OncoCyte is http://www.oncocyte.com/. How can I contact OncoCyte? OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515. MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 125 (Vote Outperform)Underperform Votes: 100 (Vote Underperform)Total Votes: 225MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: How does a security become overbought? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.